TG Therapeutics Announces Exercise of License Option For Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
September 23, 2014 at 07:31 AM EDT
TG Therapeutics, Inc. (Nasdaq: TGTX) today announced that it has exercised its option to license the global rights to TGR-1202, the ...
